» Articles » PMID: 35155136

Spectroscopic Characteristics of Xeloda Chemodrug

Overview
Date 2022 Feb 14
PMID 35155136
Authors
Affiliations
Soon will be listed here.
Abstract

Spectroscopic properties of Xeloda chemodrug have been studied over varying concentrations ranging between 0.001 and 10 mg/mL, using laser-induced fluorescence (LIF) spectroscopy. The alternative photoluminescence (PL) and near infrared (NIR) measurements are carried out to authenticate the obtained results by the LIF method. The XeCl laser as the excitation coherent source with 160 mJ/pulse at 308 nm is employed for LIF measurements of the fluorophore of interest in the modular spectroscopic set-up. Xeloda as a significant chemodrug acts as a notable fluorophore. LIF, PL and NIR spectroscopy techniques are employed to investigate the spectral properties of the chemodrug in terms of concentration. The maximum LIF peak intensity of Xeloda is achieved at λ=410.5 nm and the characteristic concentration of C=0.05 mg/mL. PL signals are in good agreement with the data given by the LIF measurements. The characteristic NIR spectra of Xeloda as solid evidence of chemical bonding formation attest to fluorescence quenching at the fluorophore concentration of 0.2 mg/ mL. Besides, the spectral shift of fluorescence signals which is obtained in terms of fluorophore concentration- demonstrating as a diagnostic marker for the purpose of optimized chemotherapy. Xeloda exhibits outstanding fluorescence properties over the allowable concentration in human serum (C). These characteristics could benefit potential advantage of simultaneous laser-based imaging of cell-chemodrug interaction over in-vivo studies.

Citing Articles

Examination of the effects of capecitabine treatment on the HT-29 colorectal cancer cell line and HCG 11, HCG 15, and HCG 18 lncRNAs in CRC patients before and after chemotherapy.

Alkharsan A, Safaralizadeh R, Khalaj-Kondori M, Hosseinpourfeizi M Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39702604 DOI: 10.1007/s00210-024-03674-8.


Hybrid laser activated phycocyanin/capecitabine treatment of cancerous MCF7 cells.

Jahdi Abdollahi S, Parvin P, Mayahi S, Seyedi S, Mohsenian P, Ramezani F Biomed Opt Express. 2022; 13(7):3939-3953.

PMID: 35991918 PMC: 9352291. DOI: 10.1364/BOE.459737.

References
1.
Albanell J, Montagut C, Jones E, Pronk L, Mellado B, Beech J . A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(9):2726-31. DOI: 10.1158/1078-0432.CCR-07-1980. View

2.
Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G . Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting. Clin Drug Investig. 2008; 28(10):645-55. DOI: 10.2165/00044011-200828100-00005. View

3.
Motlagh N, Parvin P, Ghasemi F, Atyabi F . Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin. Biomed Opt Express. 2016; 7(6):2400-6. PMC: 4918592. DOI: 10.1364/BOE.7.002400. View

4.
Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D . Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998; 4(4):941-8. View

5.
Motlagh N, Parvin P, Mirzaie Z, Karimi R, Sanderson J, Atyabi F . Synergistic performance of triggered drug release and photothermal therapy of MCF7 cells based on laser activated PEGylated GO + DOX. Biomed Opt Express. 2020; 11(7):3783-3794. PMC: 7510931. DOI: 10.1364/BOE.389261. View